Publikationen in Zusammenarbeit mit Forschern von Hospital Universitari Germans Trias i Pujol (14)

2023

  1. Virologic Response to Dolutegravir Plus Lamivudine in People With Suppressed Human Immunodeficiency Virus Type 1 and Historical M184V/I: A Systematic Literature Review and Meta-analysis

    Open Forum Infectious Diseases, Vol. 10, Núm. 11

2020

  1. Addition of maraviroc versus placebo to standard antiretroviral therapy for initial treatment of advanced HIV infection: A randomized trial

    Annals of Internal Medicine, Vol. 172, Núm. 5, pp. 297-305

  2. Primary resistance to integrase strand transfer inhibitors in Spain using ultrasensitive HIV-1 genotyping

    Journal of Antimicrobial Chemotherapy, Vol. 75, Núm. 12, pp. 3517-3524

  3. Safety and Tolerability of More than Six Days of Tedizolid Treatment

    Antimicrobial agents and chemotherapy, Vol. 64, Núm. 7

  4. Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017)

    Scientific Reports, Vol. 10, Núm. 1

2018

  1. Real world patient-reported outcomes in HIV-infected adults switching to EVIPLERA®, because of a previous intolerance to cART. PRO-STR study

    Current HIV Research, Vol. 16, Núm. 6, pp. 425-435

2017

  1. Genotypic tropism testing of proviral DNA to guide maraviroc initiation in aviraemic subjects: 48-week analysis of results from the PROTEST study

    HIV Medicine, Vol. 18, Núm. 7, pp. 482-489

  2. Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253

2015

  1. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial

    The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784

  2. Outcome of neuropsychiatric symptoms related to an antiretroviral drug following its substitution by nevirapine: The RELAX study

    HIV Medicine, Vol. 16, Núm. 10, pp. 628-634

  3. Safety, efficacy and indications of prescription of maraviroc in clinical practice: Factors associated with clinical outcomes

    Antiviral Research, Vol. 120, pp. 79-84

  4. The Efficacy and Safety of Maraviroc Addition to a Stable Antiretroviral Regimen in Subjects with Suppressed Plasma HIV-RNA is Not Influenced by Age

    AIDS Research and Human Retroviruses, Vol. 31, Núm. 9, pp. 893-897

2009

  1. Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression

    Antiviral Therapy, Vol. 14, Núm. 2, pp. 195-201

2008

  1. Low rate of adverse hepatic events associated with fosamprenavir/ritonavir-based antiretroviral regimens

    HIV Clinical Trials, Vol. 9, Núm. 5, pp. 309-313